Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified December 2012 by First Affiliated Hospital, Sun Yat-Sen University
Information provided by (Responsible Party):
Zhou Canquan, First Affiliated Hospital, Sun Yat-Sen University Identifier:
First received: December 6, 2012
Last updated: December 16, 2012
Last verified: December 2012

Polycystic Ovary Syndrome is the most common endocrine disorder in women, is estimated to affect more than 5% of the population and is associated with chronically elevated serum androgen concentrations.Evidence suggests that polycystic ovary syndrome has a negative impact on pregnancy outcomes, with an increased risk of gestational diabetes, hypertensive disease during pregnancy,and preterm birth,which is partially related with the hyperandrogenic environment.Diane-35 has been proved to be the most effective anti-androgenic drug.At present, there is no direct evidence that Diane-35 has a positive effect on the clinical outcome of polycystic ovary syndrome patients undergoing In-vitro fertilization/Intracytoplasmic sperm injection.

Condition Intervention Phase
Polycystic Ovary Syndrome
Drug: Diane-35 pretreatment
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: The Effect of Diane-35 Pretreatment on Endocrine and Clinical Profile for Patients With Polycystic Ovary Syndrome Undergoing In-vitro Fertilization

Resource links provided by NLM:

Further study details as provided by First Affiliated Hospital, Sun Yat-Sen University:

Primary Outcome Measures:
  • fertilization rate [ Time Frame: up to 2years ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • implantation rate [ Time Frame: up to 2years ] [ Designated as safety issue: Yes ]

Other Outcome Measures:
  • clinical pregnancy rate [ Time Frame: up to 2years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 100
Study Start Date: December 2012
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: diane-35
Diane-35 pretreatment from the third day of menstrual cycle
Drug: Diane-35 pretreatment
Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.
Drug: Diane-35 pretreatment
No Intervention: blank control


Ages Eligible for Study:   20 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • diagnosed polycystic ovary syndrome patients according to Rotterdam criteria
  • with hyperandrogenism and/or clinical hyperandrogenic manifestations
  • no other oral contraceptives treatment for at least 3 months before this experiment
  • no any other assisted reproductive therapy
  • accompanied with fallopian tube and/or male factors
  • normal hepato-/nephro- function

Exclusion Criteria:

  • oral contraceptive pills contraindications, eg.Deep Venous Thrombosis
  • smoking, drunk
  • exclude other infertile factors, eg.endometriosis, abnormal thyroid function, etc.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01752270

Contact: Xiaokun Hu

China, Guangdong
The First Affiliated Hospital of Sun Yatsen University Not yet recruiting
Guangzhou, Guangdong, China, 510080
Principal Investigator: Canquan Zhou         
The First Affiliated Hospital of Sun Yatsen University Not yet recruiting
Guangzhou, Guangdong, China, 510080
Principal Investigator: Canquan Zhou         
Sponsors and Collaborators
First Affiliated Hospital, Sun Yat-Sen University
  More Information

No publications provided

Responsible Party: Zhou Canquan, vice president, First Affiliated Hospital, Sun Yat-Sen University Identifier: NCT01752270     History of Changes
Other Study ID Numbers: sunyatsen8362
Study First Received: December 6, 2012
Last Updated: December 16, 2012
Health Authority: China: Food and Drug Administration

Additional relevant MeSH terms:
Polycystic Ovary Syndrome
Adnexal Diseases
Endocrine System Diseases
Genital Diseases, Female
Gonadal Disorders
Ovarian Cysts
Ovarian Diseases
Pathologic Processes
Cyproterone Acetate
Androgen Antagonists
Antineoplastic Agents
Contraceptive Agents
Contraceptive Agents, Male
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses processed this record on November 23, 2014